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Medical Management of Abdominal Aortic Aneurysm
J. Golledge1,a and J.T. Powell2*
1Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia 4811, and
2Vascular Surgery Research Group, Imperial College at Charing Cross, St Dunstan’s Road, London W6 8RP, UK
Medical management of patients with abdominal aortic aneurysm (AAA) is required for several different reasons. Since
these patients have an increased risk of cardiovascular death therapy to reduce cardiovascular events is essential. Treatment
is in line with the medical management of coronary artery disease including smoking cessation, statins and anti-platelet
therapy. Some of these therapies also will slow aneurysm growth. Currently there is no proven focused therapy that reduces
aneurysm growth, but the emerging strategies are discussed. Medical management also is required to reduce peri-operative
risks and stabilise endovascular aneurysm repair. Whilst some of the therapies targeting cardiovascular risk reduction may
be helpful, other emerging strategies are discussed.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Randomised trials have suggested that screening for
abdominal aortic aneurysm (AAA) in at risk popula-
tions can reduce related mortality.1,2 The principal
group likely to benefit are middle aged and elderly
male smokers.3 The introduction of ultrasound screen-
ing will add to the number of AAA already identified
by incidental imaging, in particular those of small
diameter.4,5 In the Aneurysm Detection And Manage-
ment study (ADAM) and a Dutch primary care screen-
ing programme >90% of the small AAAs identified
measured a maximum diameter of <55 mm.4,5 The
management of these small AAAs is usually conserva-
tive. However, the identification of an AAA also has
implications for mortality and morbidity secondary
to associated atherosclerosis.6,7 Patients with AAA
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Women with AAA may be at particularly high risk,
their death rate being twice that of the age-sex
matched population, even after successful AAA re-
pair.8 The medical management of patients with
AAA needs to be tailored to address these aspects, in
addition to monitoring AAA progression in order to
decide about open or endoluminal repair, but evidence
from randomised trials is limited (Fig. 1).
Strategies for Cardiovascular Risk Reduction
There have been no randomised trials of cardiovas-
cular risk reduction in patients with AAA, so that
current recommendations mostly derive from risk
reduction trials in patients with other cardiovascular
disease and observational studies (often retrospective)
of patients with AAA. The most important modifiable
risk factor for AAA in those with screen-detected
AAA is cigarette smoking.9 Population studies indi-
cate that smoking is associated with a relative risk of
5 for the presence of AAA. Smoking is associated with
a marked increased risk of morbidity and mortality
from a large range of other conditions, including
ischaemic heart disease, stroke, lung cancer andar Surgery. Published by Elsevier Ltd. All rights reserved.
268 J. Golledge and J. T. Powellemphysema.10 Nicotine replacement therapy and
counselling have been demonstrated to improve the
rate of smoking cessation significantly and newer treat-
ments include buproprion and varencline.11 Smoking
cessation trials are problematical, often of small size
with limited follow-up. However, smoking cessation
programmes are likely to have an important accessory
role for patients with AAA.
Dyslipidaemia and hypertension are less powerful
risk factors for AAA. The control of lipids and blood
pressure in patients with AAA is important in reduc-
ing mortality in this group. The use of statins has been
associated with an improved survival after AAA re-
pair, with a more than 3-fold reduction in risk of car-
diovascular death associated with statin usage, HR 0.3
[95%CI 0.2e0.6] p< 0.001 in a retrospective single
centre series and a similar risk reduction in the
EUROSTAR registry.12,13 Since patients with AAA
have an increased risk of cardiovascular events and
death, the results of the Heart Protection study would
suggest that all AAA patients should receive statin
therapy, irrespective of serum cholesterol concentra-
tion.14 The preferred first line drug for the treatment
of hypertension in most of these older patients is an
angiotensin converting enzyme (ACE) inhibitor.15
All these issues have been dealt with in depth in pre-
vious reviews in this series.16,17 Of greater worry is
the problem that a number of studies indicate that
management of lipids and blood pressure is often
sub-optimal in patients with AAA by comparison to
those presenting with coronary artery symptoms.18
Lloyd GM et al. have shown that patients visiting
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Fig. 1. Pathways for medical management indicated by solid
red arrows. Interrupted red arrow indicates a pathwaywhere
medical management remains to be clarified in large rando-
mised trials.
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AAA repair are being sub-optimally treated with re-
gard to current guidelines.19 Specifically, only 41%
with an indication for statin treatment have actually
received this therapy, and many others have not had
a recent plasma lipid measurement. Similar results
have been demonstrated for other pharmacological in-
terventions including anti-platelet agents, ACE inhib-
itors and beta blockers. There is increasing awareness
that the intraluminal thrombus may have a role in
AAA progression,20 but the likely benefit of anti-
platelet therapy on AAA progression has not been in-
vestigated prospectively. Nevertheless anti-platelet
therapy should be an important aspect of general car-
diovascular risk reduction in the patient with AAA.
Aspirin, in low doses (75 mg daily) remains the
drug of choice for most patients, with clopidogrel be-
ing reserved for the aspirin intolerant. Most of these
recommendations are exemplified in case study 1.
Thedevelopmentof specialist vascularphysiciansand
appropriate risk reduction clinics are important mecha-
nisms to improvemanagement of these patients. A num-
ber of non-modifiable risks for AAA, including male
gender, age and genotype impact on the development
and outcome ofAAAandwith improvedunderstanding
of these it is hoped that in the future risk modification
programs can be directed in a more individual way.
Peri-operative Medical Therapy for Those
Undergoing AAA Repair
Medical therapy to reduce cardiovascular risk is partic-
ularly critical around the time of operative intervention
to repair AAAwhen themortality for endoluminal and
open surgery are approximately 2 and 5% respec-
tively.21 The main cause of mortality is perioperative
cardiac events. In most centres patients are stratified
based on cardiac history with those at high risk for car-
diac events undergoing further imaging (see earlier
review in this series). b-Blockers have been shown to
improve peri-operative cardiac morbidity and mortal-
ity by 10-fold following major vascular surgery in the
10% of patients at highest cardiac risk.22 However, sim-
ilar benefit was not observed in those at lower risk.23
Another small randomised trial in vascular surgical
patients indicated that statin therapy reduced the com-
bined endpoint of cardiac events andmortality and this
view is supported by larger non-randomised cohort
studies of patients undergoing AAA repair; these and
other studies of peri-operative statin use have been
included in a recent systematic review.24 In patients
taking statins, the incidence of myocardial infarction
or stroke within 30 days of surgery was only 3.7%
269Aneurysm Medical Therapycompared with 11% in those not taking statins, ad-
justed hazard ratio 0.24 [95% CI 0.11e0.54]. Larger
randomised trials are required to definitely showaben-
efit of perioperative statin use.24 Case study 2 discusses
the peri-operative medical management of AAA.
Ruptured AAA
It might be considered that medical management has
no place in this condition. However, pre-operative
resuscitation guidelines should address the issue of
hypotensive haemostasis.25,26 There is evidence from
haemorrhagic trauma that mortality is reduced if
pre-operative fluid resuscitation is limited to main-
taining blood pressure at below normal levels. With
a practice of hypotensive haemostasis, some have
demonstrated excellent results for endovascular
repair of ruptured AAA, with 30-day operative mor-
tality reported to be as low as 11%.27 Although, the
selection of good prognosis patients for this approach
may partially explain the favourable outcomes.
Strategies to Reduce AAA Growth
It is likely that therapies aimed at reducing cardiovas-
cular events in patients with AAAwill also slow aneu-
rysm growth. Smoking has been associated with AAA
progression in a number of studies.28 Associations
between hypertension and dyslipidaemia with AAA
growth have been difficult to assess due to varying
definitions of these conditions, concurrent treatment
and study power.29 Pathological studies of end stage
human biopsies and those performed in animal
models have demonstrated the importance of inflam-
mation, proteolysis and vascular smooth muscle cell
loss in AAA.30 The development of specific drug ther-
apy targeted at AAA growth has engendered relative
little interest from pharmaceutical companies. Given
the cost, uncertainty and delay involved in develop-
ing medication from first principles most investiga-
tors have studied drugs in present use. The only
large randomised controlled trial investigating drug
therapy for AAA assessed the b blocker propranol.31
Due to side effects 42% of patients discontinued treat-
ment and by intention to treat analysis therapy did
not reduce AAA growth rate and significantly im-
paired quality of life.31 There are several smaller rand-
omised trials of antibiotics, with AAA growth rate as
the primary outcome measure. Animal, in vitro and
limited clinical studies provides some evidence to
support the value of a number of presently utilised
other medications discussed below.Antibiotics and MMP inhibitors
The antibiotic groups of tetracyclines and macrolides
have been shown to decrease the activity of MMPs
in cell and explant culture. Macrolides are also used
in the treatment of Chlamydia Pneumoniae, an infection
that has been associated with various atherosclerotic
conditions including AAA. Doxycycline, a tetracy-
cline, and the macrolide, roxithromycin, have shown
some promise to decrease the expansion of aneurysms
in small randomised controlled trials.32e34 However,
sample sizes and follow-up were limited in these
studies. Much larger randomised trials with long-
term, standardised patient follow up will be necessary
before these treatments can be evaluated properly.
Perhaps it is pertinent to consider why drugs with
greater selectivity for MMPs have not been used to
target reduction of AAA growth, if MMPs have
such a pivotal role in the pathogenesis of AAA.
Selective inhibitors of MMPs have been developed,
particularly with a view to preventing metastasis in
cancer, but problems with drug design, lability and
toxicity have frustrated progress of this new class of
drug.35
Statins
This class of drug inhibits 3-hydroxy 3-methylglutaryl
coenzyme A (HMG-CoA) reductase. The primary ac-
tion, pleotrophic effects and benefit in reducing car-
diovascular events have been described in detail in
an earlier review in this series.16 As a result of their
proven benefit in reducing cardiovascular events in
patients with atherosclerosis statins are being increas-
ingly used in patients with AAA. A number of the
pleotrophic effects of statins also would be expected
to reduce AAA progression. No randomised clinical
trial of statins has focused on cardiovascular events
in patients with AAA. However, two recent ultrasono-
graphic surveillance studies of small AAAs have re-
ported the association of statin use with an almost
50% reduction in AAA growth.36,37 Unfortunately it
is impossible to know whether this association simply
reflects another factor linked with statin indication or
the effect of the medication itself. The increasing
awareness that patients with peripheral artery disease
benefit from statins means it is unlikely that a suffi-
ciently powered randomised trial can now examine
the benefit of this medication for AAA. To exemplify,
a small randomised trial, closed prematurely because
of difficulties in identifying patients not taking
statins.38 Even with low recruitment this trial
showed that simvastatin reduces by 40% matrix
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AAA wall.38 The MMPs are considered to be pivotal
enzymes in the progression of AAA and in cell culture
studies and animal models statins have been demon-
strated to favourably modify proteolytic enzyme bal-
ance through reductions in MMP 1, 2, 3 and 9 and
promotion of TIMP-1 and decrease proinflammatory
cytokines (TNF-a, IL-1b and IL-6), whilst simvastatin
has been demonstrated to reduce aortic dilatation
in elastase induced AAA mouse and rat models
associated with inhibition of inflammation and
MMP-9.
Angiotensin Converting Enzyme (ACE) inhibitors
Angiotensin II has amultitude of effects that have been
linked to progression of atherosclerosis and AAA de-
velopment in addition to hypertension.17 Recently the
association of concurrent medication with admission
for AAAwas examined retrospectively in an enormous
Canadian database.39 The investigators reported an as-
sociation between ACE inhibitor use and protection
from ruptured AAA. However, given the range of med-
ications and risk factors that have to be allowed for in
this type of analysis it is impossible to be sure this is a de-
finitive association and not simply a result of multiple
statistical analyses.40
Improving the Durability of Endovascular Repair
The main cause of failure following endovascular
repair of AAA is failure to adequately exclude the
weakened aortic wall from the circulation associated
with continued aortic expansion. Approximately 20%
of patients require re-intervention for this problem
within 4 years of the primary procedure.41 At present
there are no recognised drug therapies which have
been demonstrated to improve durability of EVAR.
Since the main causes of failure to completely exclude
the aneurysm are anatomical unsuitability for EVAR
and graft failure it might be considered that medical
therapy has a small part to play in improving outcome.
However, strategies that inhibit aortic destruction may
be particularly helpful in this group in which partial
off-loading of the pressure on the aortic wall already
has occurred. In a recent prospective study of patients
undergoing endovascular AAA repair it was noted
that post-operative plasma concentrations of MMP-3
and -9 were predictive of endoleak, suggesting that
therapies targeting aortic weakening may be useful in
this group of patients.42
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AAA Therapy
Animal studies have identified a range of other medi-
cation strategies which have been demonstrated to re-
duce AAA development mostly targeting oxidative
stress, proteolysis and inflammation.29 Most of these
investigations have focused on attempts to reduce
development or slow progression of aneurysms in ani-
mals receiving themedicationof interest.A recent study
reported theuseof a c-JunN-terminalkinase inhibitor to
induce regression of AAA in mice which already had
established aneurysms.43 The investigators supported
this work with studies suggesting the importance of
c-JunN-terminal kinase inAAAdevelopment.Whether
medications of this type targeting pathology peculiar to
AAA can be developed for human use with an appro-
priate safety profile depends on a number of factors
in particular whether pharmaceutical companies are
willing to invest the substantial funds required.
Issues to Address in Randomised
Clinical Trials of AAA
Natural history studies of small AAA have identified
a number of findings which significantly impact on
the development of a randomised controlled trial.
Firstly, changes in maximal aortic diameter are slow.
Mean aortic diameter increases are reported to be be-
tween 1 and 3 mm/year in ultrasound surveillance
studies.28,44e47 These changes are within the inter-
observer measurement error reported for ultra-
sound.28 The primary factor demonstrated to influ-
ence growth rates is initial aortic diameter and
therefore it is tempting to limit an AAA medication
trial to patients with aneurysms of over 40 mm in
maximum diameter. However, conservative estimates
of intervention rates for 40e54 mm AAAs are 40% at 3
years based on two trials.48,49 Intervention rates for
these size aneurysms are likely higher in most centres
since many clinicians intervene at aortic diameters
<55 mm. Thus future trials of small AAA manage-
ment are best focused in patients with initial aortic di-
ameter under 45 mm. Trials of these size aneurysms
require long follow-up and accurate aortic imaging
in order to assess medication value. In this regard en-
try and exit CT with aortic volume and maximum or-
thogonal aortic diameter is likely to be valuable. The
calculation of mean aortic diameter changes for a treat-
ment and control group is complex, particularly when
a threshold diameter for intervention is included.25 In-
addition growth is neither regular nor linear and
complex statistical modelling is necessary to produce
unbiased estimates of AAA growth.
271Aneurysm Medical TherapyFuture Directions: Local versus Systemic
Therapy and Biomarker Directed Therapy
Since AAA often is a focal condition is would be attrac-
tive to have a locally applicable medical therapy rather
than systemic treatment which may have effects on
many other organs. The combination of a locally applied
therapy with other interventions such as endoluminal
grafting or stenting would be a possible means of reduc-
ing the requirement for re-intervention. These issues are
beginning to be investigated in experimental models of
AAA. Since natural history studies of small AAAs have
emphasised that growth is variable both between and
withinpatientsover time,28 there is aneed todevelopbio-
markers to identifypatients requiring targeted therapy to
minimise AAA growth. A large number of serum tests
and genetic markers are presently being investigated as
biomarkers to predict AAA behaviour, however, at pres-
ent thesemarkers have generally not been found to have
sufficient accuracy in modelling AAA behaviour.29 The
application of proteomic and genomic techniques to
large multicentre cohorts of AAA patients is expected
to advance the development of such biomarkers.
Case study 1
MrX is a 68yearoldman identified tohave a 4.1 cm
AAAina screeningprogram.Thepatient admits to
being a smoker for the last 40 years. On examina-
tion he is noted to have a blood pressure of 180/
90 mm Hg. What are the priorities in the medical
management of this patient?
The principal priority is to reduce the risk of cardio-
vascularevents since theriskofAAArupture is low:6
1. Control of blood pressure: Strong consideration
should be given to Angiotensin Converting
enzyme inhibitors given the suggestive evidence
for theirbenefit inreducingAAAgrowthandtheir
recommended first line use in hypertension.15,39
2. Statins: Good evidence supports the value of
this medication in this patient group even in
the absence of hypercholesterolaemia.12e14,16
3. Smoking cessation: Medication and counsel-
ling to help quit smoking is valuable.11
4. Anti-platelet medication: Aspirin or clopidog-
rel are of proven benefit in reducing cardiovas-
cular events.
5. AAA surveillance: The above measures may
slow AAA expansion, but ultrasound surveil-
lance at yearly intervals is required.Conclusions
AAA remains one of the very few common cardiovas-
cular disorders without randomised trials addressing
the issue of risk reduction and no formal guidelines
for medical therapy. Application of treatments to
reduce cardiovascular risk in line with accepted guide-
lines for coronary artery disease is needed now. Whilst
some of these treatments also may have beneficial
effects to slow aneurysm expansion, there remains
an urgent need for more targeted therapy to reduce
AAA growth, although the studies needed to validate
any such novel treatments will be complex and require
prolonged patient follow up.
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